India’s First CAR T-Cell Therapy Shows Durable Results : Two-Year Remission Achieved in Blood Cancer Patients
• Breakthrough data from Immuneel Therapeutics shows sustained remission in multiple patients treated with Varnimcabtagene autoleucel (IMN-003A) • Seven patients surpass two-year progression-free survival (PFS), a national first known for Indian CAR T therapy • Benchmark response rates recorded with 83% ORR at Day 90 and 50% at Day 365 • Over 100 patients in the real world treated to date with improved outcomes and a favorable safety profile Bengaluru, 22 May 2026: In a major milestone in Indian oncology care, Immuneel Therapeutics’ Made-In-India CAR T-cell therapy has delivered the country’s first known long-term remission in patients with aggressive blood cancers. Seven patients treated in 2022 have now surpassed two years of progression-free survival (PFS), a first for any made-in-India CAR T-cell therapy. This achievement reinforces the durability of Immuneel’s approach and its potential to transform outcomes for patients with aggressive blood cancers. The CAR T-cell ...